dexpramipexole
Phase 3- Indications
- Eosinophilic asthma, Hypereosinophilic syndrome
Company intelligence / Profile preview
Knopp Biosciences
Pittsburgh, Pennsylvania, United Statesknoppbio.com ↗
- Ownership
- Private
- Employees
- ~26
- Development stage
- Phase 3
01
Overview
Dexpramipexole showed promising Phase II results slowing ALS progression but failed Phase III trial under Biogen. Ongoing development of dexpramipexole for eosinophilic asthma via Areteia Therapeutics.
- Therapeutic areas
- PulmonologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Licensing deal with Biogen Inc. for dexpramipexole until 2014.Partnership with Population Health Partners and Bain Capital Life Sciences leading to creation of Areteia Therapeutics which now develops the Dex pipeline.Sale of Kv7 platform assets to Biohaven Pharmaceuticals Limited.
Beyond the preview
Go deeper on Knopp Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Knopp Biosciences.